Charles River investing in expanded biologics partnership with PathoQuest

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Ca-ssis)
(Image: Getty/Ca-ssis)
Charles River Laboratories and PathoQuest have expanded their strategic partnership to help move vaccine, biologic, and gene-therapy candidates through the drug discovery and development pipeline.

“The expanded partnership with PathoQuest provides our biologics clients with access to PathoQuest’s next-generation sequencing (NGS) technology,”​ said Greg Beattie, ‎corporate vice president of global biologics testing solutions at ‎Charles River Laboratories.

PathoQuest’s technology combines a proprietary sample preparation method, equipment, and a curated pathogen database with a comprehensive BioIT analysis pipeline, Beattie explained.

The NGS solution is “a powerful test for identifying adventitious agents in a single, comprehensive analysis that minimizes false negatives while also providing a tool for the genetic characterization of cell lines,”​ he told us.

Charles River will also make a direct investment in PathoQuest as part of the expanded partnership.

“We are excited to offer our customers an industry-leading technology to help progress their vaccine, biologic and gene-therapy candidates through the drug discovery and development pipeline,”​ Beattie added.

“Working with PathoQuest, we are able to leverage our existing GLP and GMP capabilities with their NGS technology to offer a customized, fast, reliable and cost-effective solution.”

Related news

Show more

Related products

show more

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars